For decades, physicians have turned to metformin as a primary tool for helping patients with type 2 diabetes keep their blood sugar under control. However, new research from Stanford University suggests that this common medication might provide a critical shield against the deadliest outcomes of Covid-19. According to a study published in the journal Diabetes, Obesity and Metabolism, adults using metformin prior to contracting the virus had a 39 percent lower risk of death in the year following their infection compared to those taking a different class of diabetes drugs known as DPP-4 inhibitors.
Scientists believe the drug’s benefits may extend far beyond simple glucose management. While high blood sugar is known to weaken the body’s immune response, researchers suggest metformin might influence specific biological pathways related to fluid balance and blood pressure that affect how severe a Covid case becomes. Some earlier data has even pointed toward the drug’s ability to dampen inflammation and reduce the amount of virus present in the body during an active infection. This mirrors similar findings from the University of Minnesota, where early administration of the drug appeared linked to better recovery rates.
Despite these promising numbers, experts are urging caution and reminding patients not to change their prescriptions based on this report. Dr. Ziyad Al-Aly, a senior clinical epidemiologist at Washington University in St. Louis, noted that people prescribed metformin are often younger and healthier overall than those on DPP-4 inhibitors, who frequently suffer from kidney disease or other complications. Because this was an observational study based on medical records rather than a controlled clinical trial, it remains unclear if metformin itself caused the higher survival rate or if it was simply reflective of a healthier patient group.
Medical professionals emphasize that there is currently not enough evidence to shift standard treatment protocols. Since many patients take alternative medications specifically because they cannot tolerate metformin, switching without professional guidance could be dangerous. Researchers conclude that while these findings open an exciting door into how we treat diabetic patients during respiratory infections, larger randomized trials are necessary before any official changes to medical guidelines can be made.
